Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cagrilintide vs Tirzepatide
An educational, source-based comparison of Cagrilintide and Tirzepatide — how each peptide works, what it's researched for, and what to know before going deeper.
A long-acting analog of amylin, a pancreatic hormone co-secreted with insulin. It slows gastric emptying, increases satiety, and suppresses glucagon — complementary to GLP-1 mechanisms.
- Weight management as monotherapy and combined with semaglutide (CagriSema)
- Glycemic control in type 2 diabetes
- • Investigational; not yet FDA-approved as monotherapy.
- • GI side effects similar to GLP-1 agonists.
A dual agonist of the GLP-1 and GIP receptors. The combined incretin action improves glucose control and produces greater weight loss than GLP-1 monotherapy in head-to-head trials.
- Type 2 diabetes (Mounjaro)
- Chronic weight management (Zepbound)
- Sleep apnea in obesity (recent approval)
- • FDA-approved; requires prescription and physician oversight.
- • GI side effects are dose-limiting.
- • Compounded versions are not FDA-evaluated.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Cagrilintide | Cagrilintide plus semaglutide for obesity (Phase 2) | The Lancet | 2021 | Combination produced greater weight loss than either agent alone. |
| Tirzepatide | Tirzepatide once weekly for weight management (SURMOUNT-1) | New England Journal of Medicine | 2022 | Up to ~21% mean weight loss at 72 weeks at the highest dose. |
Side-effect & safety grid
- Investigational; not yet FDA-approved as monotherapy.
- GI side effects similar to GLP-1 agonists.
- FDA-approved; requires prescription and physician oversight.
- GI side effects are dose-limiting.
- Compounded versions are not FDA-evaluated.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Cagrilintide vs Tirzepatide — Key differences
- Class: Cagrilintide is classified as Metabolic · Amylin, while Tirzepatide is Metabolic · Incretin.
- Primary research focus: Cagrilintide — weight management as monotherapy and combined with semaglutide (cagrisema); Tirzepatide — type 2 diabetes (mounjaro).
- Tag: Weight loss vs Weight loss.
Tirzepatide — Frequently Asked Questions
What is tirzepatide?+
Tirzepatide is an FDA-approved dual GIP and GLP-1 receptor agonist given as a once-weekly subcutaneous injection, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and for obstructive sleep apnea in adults with obesity.
How much weight loss is reported with tirzepatide?+
SURMOUNT-1 reported mean weight reduction of about 21% at 72 weeks on the highest dose in adults with obesity and without diabetes, versus about 3% on placebo. Results vary by dose and by whether type 2 diabetes is present.
How is tirzepatide dosed?+
Approved labeling starts at 2.5 mg once weekly for four weeks as a tolerability step, then increases in 2.5 mg increments no more often than every four weeks, up to a maximum of 15 mg weekly. Titration is set by the prescriber.
What makes tirzepatide different from a GLP-1-only drug?+
It also activates the GIP receptor. GIP agonism is thought to add to appetite regulation and improve insulin sensitivity signaling, and it is the mechanistic explanation usually given for the larger weight and HbA1c effects seen versus semaglutide in SURPASS-2 and SURMOUNT-5.
What side effects are most reported with tirzepatide?+
Gastrointestinal effects dominate — nausea, diarrhea, vomiting, constipation, and reduced appetite — and are typically dose-limiting. Labeling carries a boxed warning for thyroid C-cell tumors observed in rodents; gallbladder events and pancreatitis are also listed.
Is compounded tirzepatide legitimate?+
Compounded tirzepatide is not FDA-evaluated for safety, efficacy, or quality. The FDA has issued warnings about the compounded incretin market, including unapproved salt forms and dosing errors, so it is not equivalent to the approved product.
Can tirzepatide be used with other peptides?+
There is no clinical evidence supporting combinations of tirzepatide with research peptides, and stacking is not studied in trials. Any combination question belongs with a licensed prescriber who can review the full medication list.